AR013949A1 - Utilizacion de inhibidores del intercambiador entre sodio e hidrogeno para la preparacion de un medicamento destinado al tratamiento de enfermedades que son provocadas por protozoos - Google Patents

Utilizacion de inhibidores del intercambiador entre sodio e hidrogeno para la preparacion de un medicamento destinado al tratamiento de enfermedades que son provocadas por protozoos

Info

Publication number
AR013949A1
AR013949A1 ARP980104256A ARP980104256A AR013949A1 AR 013949 A1 AR013949 A1 AR 013949A1 AR P980104256 A ARP980104256 A AR P980104256A AR P980104256 A ARP980104256 A AR P980104256A AR 013949 A1 AR013949 A1 AR 013949A1
Authority
AR
Argentina
Prior art keywords
preparation
treatment
bovine
pathogenic
inhibitors
Prior art date
Application number
ARP980104256A
Other languages
English (en)
Original Assignee
Gompel Marie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gompel Marie filed Critical Gompel Marie
Publication of AR013949A1 publication Critical patent/AR013949A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Los inhibidores del intercambiador de sodio e hidrogeno se adecuan a solas o en combinacion con otras clases de sustancias activas para la preparacion deun medicamento destinado al tratamiento de enfermedades que son provocadas por protozoos patogenos en veterinaria y en seres humanos, tal como por parásitosactivos intracelularmente de las clases de parásitos activos intracelularmente de las clases Apicom]lexa y Zoomastigophora, especialmente Tripanosomas,Plasmodios (patogenos de malaria), Leishmanias, Babesias y Theilerías, Criptosporididas, Sarcocístidas, amebas, Coccidios y Tricomonas. De modoespecialmente preferido los inhibidores del IHE se adecuan para la preparacion de un medicamento destinado al tratamiento de la malaria tropical, de lamalaria terciana, de la malaria cuartana, de la toxoplasmosis, de la coccidiosis, de la sarcoporidosis intestinal, de la criptosporidosis, de laenfermedad de Chagas y de las formas cutáneas y viscerales así como otros tipos deleishmaniosis, así como para la preparacion de un medicamento destinado al tratamiento de animales, que habían sido afectados por protozoos patogenos enveterinaria, tal como son provocados por Theileria parva, el agente patogeno de la fiebrede la Costa Oriental de reses de bobino, Babesia begemina, el agentepatogeno de la fiebre de Texas en reses de bovino y bufalos, Babesia bovis, el agente patogeno de la babesiosis bovina europea, así como babesiosis en perros,gatos y corderos, Sarcocystidae, los agentes patogenos de sarcocistosis en animales ovinos, bovinos y porcinos, Cryptosporidiidae, los agentes patogenosde criptosporidosis en animales bovinos y aves, Coccidios, los agentes patogenos de animales cunidos, bovinos, ovinos, caprinos y porcinos, pero
ARP980104256A 1997-08-28 1998-08-26 Utilizacion de inhibidores del intercambiador entre sodio e hidrogeno para la preparacion de un medicamento destinado al tratamiento de enfermedades que son provocadas por protozoos AR013949A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19737463A DE19737463A1 (de) 1997-08-28 1997-08-28 Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden

Publications (1)

Publication Number Publication Date
AR013949A1 true AR013949A1 (es) 2001-01-31

Family

ID=7840411

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980104256A AR013949A1 (es) 1997-08-28 1998-08-26 Utilizacion de inhibidores del intercambiador entre sodio e hidrogeno para la preparacion de un medicamento destinado al tratamiento de enfermedades que son provocadas por protozoos

Country Status (26)

Country Link
US (1) US6114393A (es)
EP (1) EP0901788A3 (es)
JP (1) JPH11171792A (es)
KR (1) KR100567144B1 (es)
CN (1) CN1244322C (es)
AR (1) AR013949A1 (es)
AU (1) AU738599B2 (es)
BR (1) BR9803243A (es)
CA (1) CA2246407A1 (es)
CZ (1) CZ296815B6 (es)
DE (1) DE19737463A1 (es)
HK (1) HK1018589A1 (es)
HR (1) HRP980468A2 (es)
HU (1) HU225583B1 (es)
ID (1) ID20794A (es)
IL (1) IL125946A0 (es)
MY (1) MY137406A (es)
NO (1) NO320368B1 (es)
NZ (1) NZ331566A (es)
PL (1) PL191267B1 (es)
RU (1) RU2225726C2 (es)
SG (1) SG74074A1 (es)
SK (1) SK285457B6 (es)
TR (1) TR199801669A2 (es)
TW (1) TW592690B (es)
ZA (1) ZA987781B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224739D0 (en) * 1992-11-26 1993-01-13 Wellcome Found Medicaments
CA2395333C (en) * 1999-12-23 2009-01-13 Pfizer Products Inc. Hydrogel-driven drug dosage form
US7375138B2 (en) 2002-05-18 2008-05-20 Sanofi-Aventis Deutschland Gmbh Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them
FR2840302B1 (fr) * 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
US6878748B2 (en) 2002-06-13 2005-04-12 Aventis Pharma Deutschland Gmbh Fluorinated cycloalkyl-derivatized benzoylguanidines, process for their preparation, their uses as medicament, and medicament containing them
LT3649109T (lt) * 2017-07-04 2021-09-27 Sanofi Etinilo junginiai, jų gamyba ir jų terapinis panaudojimas maliarijos gydymui

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1336871A (en) * 1970-01-02 1973-11-14 Wellcome Found Method for preparing biologically active substituted amidines
US4088780A (en) * 1974-05-15 1978-05-09 Bayer Aktiengesellschaft Substituted phenylguanidines and processes for their preparation and use
US4032655A (en) * 1974-05-15 1977-06-28 Bayer Aktiengesellschaft Phenylguanidines useful as anthelmintic agents
US4544670A (en) * 1982-08-24 1985-10-01 William H. Rorer, Inc. Method of treating coccidiosis with acyl guanidines
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
IN172842B (es) * 1990-05-17 1993-12-11 Boots Pharmaceuticals Limited
US5352667A (en) * 1991-11-22 1994-10-04 Ofer Lider Non-peptidic surrogates of the Arg-Gly-Asp sequence and pharmaceutical compositions comprising them
CZ284456B6 (cs) * 1992-02-15 1998-12-16 Hoechst Aktiengesellschaft Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje
GB9224739D0 (en) * 1992-11-26 1993-01-13 Wellcome Found Medicaments
DE4318658A1 (de) * 1993-06-04 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4318756A1 (de) * 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19502644A1 (de) * 1995-01-28 1996-08-01 Merck Patent Gmbh 4-Amino-benzoylguanidin-Derivate
FR2734263B1 (fr) * 1995-05-17 1997-06-20 Fournier Ind & Sante Analogues de la 15-deoxyspergualine, leur procede de preparation et leur utilisation en therapeutique
CA2223910C (en) * 1995-06-07 2008-09-16 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (nhe), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the nhe-inhibitory efficacy of compounds
DE19542306A1 (de) * 1995-11-14 1997-05-15 Hoechst Ag Sulfonylamino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
HU225583B1 (en) 2007-03-28
SK285457B6 (sk) 2007-02-01
KR19990023905A (ko) 1999-03-25
HU9801925D0 (en) 1998-10-28
NO983943D0 (no) 1998-08-27
BR9803243A (pt) 2000-03-21
TR199801669A3 (tr) 1999-03-22
CN1209994A (zh) 1999-03-10
KR100567144B1 (ko) 2006-11-30
CZ296815B6 (cs) 2006-06-14
CA2246407A1 (en) 1999-02-28
NO320368B1 (no) 2005-11-28
EP0901788A2 (de) 1999-03-17
HUP9801925A3 (en) 2004-11-29
CZ272998A3 (cs) 1999-03-17
ZA987781B (en) 1999-05-27
HRP980468A2 (en) 1999-06-30
PL191267B1 (pl) 2006-04-28
JPH11171792A (ja) 1999-06-29
CN1244322C (zh) 2006-03-08
DE19737463A1 (de) 1999-03-04
SG74074A1 (en) 2000-07-18
TR199801669A2 (xx) 1999-03-22
TW592690B (en) 2004-06-21
US6114393A (en) 2000-09-05
AU738599B2 (en) 2001-09-20
MY137406A (en) 2009-01-30
NZ331566A (en) 2001-03-30
RU2225726C2 (ru) 2004-03-20
HUP9801925A1 (hu) 2000-02-28
NO983943L (no) 1999-03-01
ID20794A (id) 1999-03-04
EP0901788A3 (de) 2004-01-02
PL328265A1 (en) 1999-03-01
AU8189498A (en) 1999-03-11
IL125946A0 (en) 1999-04-11
HK1018589A1 (en) 1999-12-30
SK117498A3 (en) 1999-03-12

Similar Documents

Publication Publication Date Title
ES2234236T3 (es) Feromonas calmantes del cerdo para disminuir el estres, la ansiedad y la agresividad.
ES2063011T3 (es) Agentes antibacteriales de quinolonas y naftiridinas que contienen un alfa-aminoacido en la cadena lateral del 7-sustituyente.
ES2565190T3 (es) Reducción de mareos, un efecto secundario asociado a la terapia de pirfenidona
Gonzales et al. Therapeutic and persistent efficacy of doramectin against Boophilus microplus in cattle
ECSP056074A (es) Composiciones y método para tratar las infecciones microbianas y parasitarias en el ganado y otros animales
ECSP056189A (es) Composiciones y método para el tratamiento de infecciones en ganado vacuno y porcino
CO5611162A2 (es) Metodos para prevenir enfermedades reproductivas en el ganado vacuno
ES2038122T3 (es) Un procedimiento para la preparacion de una composicion veterinaria2.
AR013949A1 (es) Utilizacion de inhibidores del intercambiador entre sodio e hidrogeno para la preparacion de un medicamento destinado al tratamiento de enfermedades que son provocadas por protozoos
ES2149740T3 (es) Dispositivo de inseminacion artificial para animales de cria tales como, particularmente, cerdas.
AR021690A1 (es) Empleo de inhibidores del canal de ktq1 para la preparacion de un medicamento para el tratamiento de enfermedades, que son provocadas por helmintos yectoparasitos.
AR019579A1 (es) USO DE UN INICIADOR DE LA RESPUESTA SEXUAL DEL SISTEMA NERVIOSO CENTRAL PARA LA FABRICACIoN DE UNA COMPOSICIoN FARMACÉUTICA PARA LA NORMALIZACIoN DE LA CRONOMETRACIoN DE LA RESPUESTA SEXUAL O PARA LA PROFILAXIS O REDUCCIoN DE LA LESIoN TISULAR GENITAL EN MAMíFEROS
McMeekan et al. Effects of shallow scoop and deep scoop dehorning on plasma cortisol concentrations in calves
Prunier et al. Endocrine and behavioural responses of sows to human interactions and consequences on reproductive performance
Hogue et al. Fertility of ewes bred naturally and artificially after estrous cycle synchronization with an oral progestational agent
ES2064669T3 (es) Raciones que proporcionan resistencia a las enfermedades y aditivo alimentario para ganado vacuno o porcino.
PE117199A1 (es) Formulaciones parasiticidas
Olias et al. The significance of cryptosporidiosis for the health of calves in Switzerland
PH27250A (en) The use of naphthoquinones against toxoplasmosis
Holden et al. Operant‐conditioning programme for White rhinoceros, Black rhinoceros and Indian or Greater one‐horned Asian rhinoceros Ceratotherium simum, Diceros bi cornis and Rhinoceros unicornis at Whipsnade Wild Animal Park, Dunstable, UK
Richey Management of anaplasmosis in beef cattle
RU2267269C1 (ru) Способ стимуляции репродуктивной функции свиноматок
Alawa ANP 506 ANIMAL HEALTH AND DISEASES
RU2258498C2 (ru) Способ стимуляции репродуктивной функции свиноматок
BR9712633A (pt) Método para o tratamento de infecção por streptococcus pneumoniae

Legal Events

Date Code Title Description
FB Suspension of granting procedure